Protalix is a publicly traded clinical stage biopharmaceutical company
that is focused on developing and manufacturing of recombinant
therapeutic proteins. Protalix uses its proprietary plant cell culture and
bioreactor technology for the expression of recombinant therapeutic
proteins, and is currently developing several biopharmaceutical
Our patented plant cell contained bioreactor system enables the
expression of specific human genes, encoding expression for proteins
of pharmaceutical or therapeutic value. Subsequently, the expressed
protein of interest is extracted from the plant cells and purified to a
Our lead product under development is prGCD, an enzyme for the
treatment of Gaucher disease. We completed a Phase I clinical
trial under FDA Investigational New Drug (IND) approval to assess
the safety of prGCD in healthy volunteers. All doses administered
to subjects in the Phase I clinical trial demonstrated a good safety
Protalix is currently running Phase III clinical trials in major medical
centers worldwide to assess the safety and efficacy of prGCD in
Gaucher disease patients.
Additionally, we have an innovative product pipeline, including various
proprietary therapeutic protein candidates, which will enable us to
progress to preclinical studies for additional products during 2008.
Protalix established a GMP bio-manufacturing plant and state-of-theart
research facility for the development and large-scale production of
clinical grade proteins in Israel.
Key Advantages of our ProCellEx expression system:
Enables penetration of patent protected markets.
Flexible polyethylene bioreactors entail very low initial capital investment.
Requires less costly hands-on maintenance.
Significant advantages over cell based mammalian systems
Watch movie >>